State Street Corp lifted its position in Savara Inc (NASDAQ:SVRA - Free Report) by 15.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,138,276 shares of the company's stock after acquiring an additional 560,242 shares during the quarter. State Street Corp owned approximately 2.41% of Savara worth $17,546,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in SVRA. Choreo LLC purchased a new stake in Savara in the 2nd quarter valued at about $59,000. DRW Securities LLC bought a new position in shares of Savara in the second quarter valued at approximately $62,000. Principal Financial Group Inc. grew its holdings in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock valued at $72,000 after acquiring an additional 6,973 shares in the last quarter. Profund Advisors LLC purchased a new stake in shares of Savara during the second quarter valued at approximately $105,000. Finally, BNP Paribas Financial Markets lifted its holdings in Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock worth $109,000 after acquiring an additional 18,534 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. JMP Securities reiterated a "market outperform" rating and set a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 target price on the stock. Evercore ISI reaffirmed an "in-line" rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright reduced their price objective on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.86.
Check Out Our Latest Stock Analysis on SVRA
Savara Stock Performance
Shares of NASDAQ SVRA traded down $0.05 during mid-day trading on Wednesday, hitting $3.20. The company had a trading volume of 1,036,291 shares, compared to its average volume of 1,276,668. The stock's 50-day moving average price is $3.45 and its 200-day moving average price is $3.97. The company has a market capitalization of $549.18 million, a price-to-earnings ratio of -7.44 and a beta of 0.92. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 1 year low of $2.82 and a 1 year high of $5.70.
Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, sell-side analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Joseph S. Mccracken purchased 20,000 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average price of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now directly owns 210,837 shares of the company's stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company's stock, valued at $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by company insiders.
About Savara
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
